argenx SE logo

argenx SE

ARGX
Healthcare|Biotechnology|Netherlands
$877.29
-31.87 (-3.50%)
DCF (FCF)
$17.80
Tangible Book
$111.77
Graham Number
$215.25

Upcoming Data Readouts (31)

Nov 2026
Est. completion
P2Dermatomyositis
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
NCT06284954n=3
Dec 2026
Est. completion
P2P3Active Idiopathic Inflammatory Myopathy
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167n=265
Dec 2026
Est. completion
P2Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
NCT06453694n=20
Dec 2026
Est. completion
P1Healthy Volunteers (HV)
A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants
NCT07673601n=52
Dec 2026
Est. completion
P1Healthy Volunteers
A Study to Assess the Safety of ARGX-124 in Healthy Volunteers
NCT07377396n=104
Dec 2026
Est. completion
P4Myasthenia Gravis Crisis
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06860633n=20
Jan 2027
Est. completion
P3Myasthaenia Gravis
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
NCT06765161n=30
Feb 2027
Est. completion
P2Systemic Sclerosis (SSc)
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155n=81
Mar 2027
Est. completion
P2P3Generalized Myasthenia Gravis
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894n=12
Mar 2027
Est. completion
P1Healthy Volunteers
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
NCT07612020n=130
Apr 2027
Est. completion
P2Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718n=229
May 2027
Est. completion
P1Leukemia, Myeloid, Acute
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
NCT04150887n=61
Jun 2027
Est. completion
Congenital Myasthenic Syndrome
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553n=100
Jul 2027
Est. completion
P3Primary Sjogrens Disease
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847n=631
Aug 2027
Est. completion
P1Congenital Myasthenic Syndrome
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742n=16
Sep 2027
Est. completion
P3Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004n=218
Oct 2027
Est. completion
P3Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630n=160
Nov 2027
Est. completion
Generalized Myasthenia Gravis (gMG)
A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy
NCT07595653n=100
Nov 2027
Est. completion
P2Antibody-mediated Rejection
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731n=33
Mar 2028
Est. completion
P2AChR-Ab Seropositive Generalized Myasthenia Gravis
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
NCT07284420n=70

Awaiting Results (7)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026
P3
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925
Sep 2026
P3
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190
Aug 2026
P2
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT06441682
Jan 2026
P3
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279
Oct 2025
P2
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
NCT05907096
Jun 2025
P3
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552
Aug 2023
P2
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
NCT04023526

Recent Press Releases